[go: up one dir, main page]

SI2099826T1 - Anti-beta-amiloidno protitelo in njegova uporaba - Google Patents

Anti-beta-amiloidno protitelo in njegova uporaba

Info

Publication number
SI2099826T1
SI2099826T1 SI200831130T SI200831130T SI2099826T1 SI 2099826 T1 SI2099826 T1 SI 2099826T1 SI 200831130 T SI200831130 T SI 200831130T SI 200831130 T SI200831130 T SI 200831130T SI 2099826 T1 SI2099826 T1 SI 2099826T1
Authority
SI
Slovenia
Prior art keywords
beta
amyloid antibody
amyloid
antibody
Prior art date
Application number
SI200831130T
Other languages
English (en)
Inventor
Roger Nitsch
Christoph Hock
Christoph Esslinger
Marlen Knobloch
Kathrin Tissot
Jan Grimm
Original Assignee
University Of Zurich Prorektorat Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2099826(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University Of Zurich Prorektorat Forschung filed Critical University Of Zurich Prorektorat Forschung
Publication of SI2099826T1 publication Critical patent/SI2099826T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
SI200831130T 2007-01-05 2008-01-07 Anti-beta-amiloidno protitelo in njegova uporaba SI2099826T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US87883107P 2007-01-05 2007-01-05
EP07000211 2007-01-05
US93429107P 2007-06-11 2007-06-11
EP07020341 2007-10-17
EP08700998.1A EP2099826B1 (en) 2007-01-05 2008-01-07 Anti-beta-amyloid antibody and uses thereof
PCT/EP2008/000053 WO2008081008A1 (en) 2007-01-05 2008-01-07 Method of providing disease-specific binding molecules and targets

Publications (1)

Publication Number Publication Date
SI2099826T1 true SI2099826T1 (sl) 2014-02-28

Family

ID=39186163

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200831845T SI2436696T1 (sl) 2007-01-05 2008-01-07 Anti-beta-amiloidno protitelo in načini njegove uporabe
SI200831130T SI2099826T1 (sl) 2007-01-05 2008-01-07 Anti-beta-amiloidno protitelo in njegova uporaba

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200831845T SI2436696T1 (sl) 2007-01-05 2008-01-07 Anti-beta-amiloidno protitelo in načini njegove uporabe

Country Status (20)

Country Link
US (1) US8906367B2 (sl)
EP (5) EP3239174A1 (sl)
JP (1) JP5398545B2 (sl)
KR (4) KR20090114388A (sl)
CN (3) CN103408661B (sl)
AU (1) AU2008203703C1 (sl)
BR (1) BRPI0806328B8 (sl)
CA (2) CA2764852C (sl)
CY (1) CY1119197T1 (sl)
DK (3) DK2099826T3 (sl)
EA (2) EA017611B1 (sl)
ES (3) ES2439490T3 (sl)
HU (2) HUE034512T2 (sl)
LT (1) LT2436696T (sl)
MX (1) MX2009007136A (sl)
PL (3) PL2099826T3 (sl)
PT (3) PT2426143T (sl)
SG (1) SG177954A1 (sl)
SI (2) SI2436696T1 (sl)
WO (1) WO2008081008A1 (sl)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
CN103408661B (zh) * 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
EP2134746B1 (en) 2007-03-13 2014-08-06 University Of Zurich Monoclonal human tumor-specific antibody
JP2011527338A (ja) * 2008-07-09 2011-10-27 ユニバーシティー オブ チューリッヒ 神経新生を促進する方法
EP2186827A1 (en) 2008-11-14 2010-05-19 HS LifeSciences Ltd. Surrogate marker directed cDNA cloning of selectively induced mRNAs
DK2949666T3 (en) 2008-12-19 2019-03-25 Biogen Int Neuroscience Gmbh HUMAN ANTI-ALPHA SYNUCLEIN ANTIBODIES
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
EP2609431B1 (en) 2010-08-27 2017-05-10 University of Zurich Method for target and drug validation in inflammatory and/or cardiovascular diseases
JP2013540991A (ja) 2010-08-27 2013-11-07 ユニバーシティ・オブ・チューリッヒ 炎症および／または心血管疾患における新規診断および治療標的
SG189174A1 (en) 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
JP6030452B2 (ja) 2010-11-30 2016-11-24 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
WO2012080518A1 (en) 2010-12-17 2012-06-21 Neurimmune Holding Ag Human anti-sod1 antibodies
US20140044644A1 (en) 2011-02-21 2014-02-13 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
MX361713B (es) 2011-09-30 2018-12-14 Chugai Pharmaceutical Co Ltd Molécula de unión al antígeno para promover la eliminación de antígenos.
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6352634B2 (ja) 2011-09-30 2018-07-04 中外製薬株式会社 標的抗原に対する免疫応答を誘導する抗原結合分子
JP6271251B2 (ja) 2011-10-05 2018-01-31 中外製薬株式会社 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
US20130095118A1 (en) * 2011-10-11 2013-04-18 Vaccinex, Inc. Use of Semaphorin-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability
WO2013063086A1 (en) * 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
JP6240611B2 (ja) * 2011-10-28 2017-11-29 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー Ｔｄｐ−４３に特異的な結合分子
CA2854131C (en) 2011-11-02 2020-07-07 Andreas Weihofen Use of an anti-.alpha.-synuclein antibody to diagnose an elevated level of .alpha.-synuclein in the brain
SG10201609301QA (en) 2011-11-30 2016-12-29 Chugai Pharmaceutical Co Ltd Drug containing carrier into cell for forming immune complex
DE102011057019A1 (de) * 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Standard zur Quantifizierung von pathogenen Aggregaten aus körpereigenen Proteinen
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
EP2797951B1 (en) 2011-12-28 2018-01-31 ImmunoQure AG Method of isolating human antibodies
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
CN104619724B (zh) * 2012-01-27 2018-05-04 普罗典娜生物科学有限公司 识别α-突触核蛋白的人源化抗体
US20150210763A1 (en) 2012-02-09 2015-07-30 Chugai Seiyaku Kabushiki Kaisha MODIFIED Fc REGION OF ANTIBODY
KR102219987B1 (ko) 2012-02-24 2021-02-25 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자
KR102413947B1 (ko) 2012-05-30 2022-06-27 추가이 세이야쿠 가부시키가이샤 표적 조직 특이적 항원 결합 분자
EP2857419B1 (en) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
EP2928494A4 (en) * 2012-12-07 2016-11-02 Biogen Internat Neuroscience Gmbh METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES
KR102234324B1 (ko) 2012-12-21 2021-03-31 바이오젠 엠에이 인코포레이티드 인간 항-타우 항체
JP6592426B2 (ja) 2013-03-15 2019-10-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製
CN105517571A (zh) 2013-06-24 2016-04-20 中外制药株式会社 含有人源化抗上皮调节蛋白抗体作为有效成分的腺癌以外的非小细胞肺癌的治疗药
AU2014284809B2 (en) * 2013-07-03 2016-12-15 Seoul National University R&Db Foundation Chicken antibody transformed into cysteine and site-specific conjugation using same
US20160177390A1 (en) * 2013-07-12 2016-06-23 Biogen International Neuroscience Gmbh Genetic and image biomarkets associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease
EP3047857A4 (en) 2013-09-20 2017-08-09 Chugai Seiyaku Kabushiki Kaisha Treatment for hemorrhagic diseases by anti-protein-c antibody
CN111499742B (zh) 2013-11-21 2024-05-07 豪夫迈·罗氏有限公司 抗-α-突触核蛋白抗体及使用方法
CN105980557B (zh) 2013-12-04 2020-04-07 中外制药株式会社 抗原结合能力根据化合物的浓度而变化的抗原结合分子及其文库
SG11201604831QA (en) * 2013-12-20 2016-08-30 Neurimmune Holding Ag Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
AU2015279089B2 (en) * 2014-06-26 2021-01-28 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) * 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EP4406549A3 (en) * 2014-07-29 2025-01-08 Neurimmune Holding AG Human-derived anti-huntingtin (htt) antibodies and uses thereof
JP6637971B2 (ja) 2014-09-30 2020-01-29 ニューリミューン ホールディング エイジー ヒト由来の抗ジペプチドリピート（ｄｐｒ）抗体
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3280738A4 (en) 2015-04-08 2019-01-02 Nantomics, LLC Cancer neoepitopes
CA2988388C (en) 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
WO2017066290A1 (en) * 2015-10-12 2017-04-20 Nantomics, Llc Viral neoepitopes and uses thereof
JP2018532736A (ja) 2015-10-12 2018-11-08 ナントミクス，エルエルシー チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法
US11340225B2 (en) * 2016-03-14 2022-05-24 Biogen International Neuroscience Gmbh Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP7481726B2 (ja) 2016-05-02 2024-05-13 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
EA201892412A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
BR112018075300A2 (pt) * 2016-06-07 2019-04-30 Biogen International Neuroscience Gmbh métodos para tratamento do mal de alzheimer
RU2766711C2 (ru) * 2016-06-29 2022-03-15 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния СТРУКТУРНЫЕ ПЕПТИДНЫЕ ИНГИБИТОРЫ АГРЕГАЦИИ α-СИНУКЛЕИНА
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
EP3487880A1 (en) 2016-07-25 2019-05-29 Biogen MA Inc. Anti-hspa5 (grp78) antibodies and uses thereof
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
WO2018112362A1 (en) 2016-12-16 2018-06-21 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
KR101989383B1 (ko) * 2017-04-04 2019-06-14 조선대학교산학협력단 알츠하이머성 치매의 조기진단을 위한 펩타이드 프로브
AU2018263935B2 (en) 2017-05-02 2024-09-26 Prothena Biosciences Limited Antibodies recognizing tau
CN109201128A (zh) * 2017-07-05 2019-01-15 京东方科技集团股份有限公司 微流控芯片、化学发光免疫分析系统和分析方法
EP4233901A3 (en) * 2017-08-22 2023-09-06 Biogen MA Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
CN108484761B (zh) * 2018-03-10 2021-04-30 吉林大学 一种特异性识别并诱导Aβ42的寡聚体及原纤维解聚的单链抗体、单链抗体基因及其应用
CN108874749B (zh) * 2018-06-22 2022-10-14 西南科技大学 一种高考志愿录取概率模型的建立方法
WO2020015637A1 (zh) 2018-07-17 2020-01-23 江苏恒瑞医药股份有限公司 抗Abeta抗体、其抗原结合片段及应用
EP3836966A4 (en) * 2018-08-17 2022-06-08 Ab Studio Inc. CATALYTIC ANTIBODIES AND THEIR METHODS OF USE
SG11202102765RA (en) * 2018-10-04 2021-04-29 Georg August Universitaet Goettingen Stiftung Oeffentlichen Rechts Universitaetsmedizin Humanised anti-n-truncated amyloid beta monoclonal antibody
MA54070A (fr) 2018-10-29 2021-09-08 Biogen Ma Inc Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique
CN111518206B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN111518205B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN111518207B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
KR102135130B1 (ko) * 2019-02-15 2020-07-17 충북대학교 산학협력단 트랜스타이레틴 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
US11851487B2 (en) * 2019-04-01 2023-12-26 Rensselaer Polytechnic Institute Methods and systems for detecting peptide aggregates
CA3158513A1 (en) 2019-10-22 2021-04-29 Biogen Ma Inc. Methods for treating alzheimer's disease
WO2021079002A2 (en) 2019-10-24 2021-04-29 Novago Therapeutics Ag Novel anti-nogo-a antibodies
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
WO2021236809A2 (en) 2020-05-19 2021-11-25 Othair Prothena Limited Multi-epitope vaccine for the treatment of alzheimer's disease
US20230242624A1 (en) 2020-06-02 2023-08-03 Neurimmune Ag HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
WO2021263279A1 (en) 2020-06-24 2021-12-30 Prothena Biosciences Limited Antibodies recognizing sortilin
CN116209678A (zh) 2020-07-01 2023-06-02 安尔士制药公司 抗asgr1抗体缀合物及其用途
US20220049009A1 (en) 2020-07-23 2022-02-17 Othair Prothena Limited Anti-Abeta Antibodies
CN114252628A (zh) * 2020-09-24 2022-03-29 首都医科大学附属北京世纪坛医院 尿液再生蛋白及其多肽片段在过敏性疾病中的应用
CN114252607A (zh) * 2020-09-24 2022-03-29 首都医科大学附属北京世纪坛医院 尿液v-atpase亚基s1及其多肽片段在过敏性疾病中的应用
WO2022144406A1 (en) 2020-12-29 2022-07-07 Neurimmune Ag Human anti-tau antibodies
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
KR20240028975A (ko) 2021-04-08 2024-03-05 사나 바이오테크놀로지, 인크. Cd8-특이적 항체 구조체들 및 이의 조성물
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CA3223179A1 (en) 2021-06-11 2022-12-15 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
CN117586388A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 改进的β淀粉样蛋白寡聚体特异性结合抗体
WO2024087430A1 (zh) * 2023-02-28 2024-05-02 湖南乾康科技有限公司 一种用于定量检测尿液淀粉样前体蛋白片段的酶联免疫检测方法
WO2024229290A1 (en) 2023-05-02 2024-11-07 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of use thereof

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
EP0428534B1 (en) 1988-06-14 1995-03-29 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DK0656950T3 (da) 1992-08-21 1999-07-19 Biogen Inc TAT-afledte transportpolypeptider
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
EP0669986B1 (en) 1992-11-13 2003-04-09 Idec Pharmaceuticals Corporation Fully impaired consensus kozac sequences for mammalian expression
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5875396A (en) * 1995-11-13 1999-02-23 Wytec, Incorporated Multichannel radio frequency transmission system to deliver wideband digital data into independent sectorized service areas
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
BR9808584A (pt) 1997-03-14 2000-05-23 Idec Pharma Corp Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US20020086847A1 (en) * 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
NZ337765A (en) 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
US6703015B1 (en) * 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
ATE536422T1 (de) 1998-08-25 2011-12-15 Univ Washington Schnelle quantitative analyse von proteinen oder proteinfunktionen in komplexen gemischen
AU1631700A (en) 1998-11-23 2000-06-13 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
US6361973B1 (en) * 1999-03-22 2002-03-26 Novozymes Biotech, Inc. Promoters for expressing genes in a fungal cell
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
DE19932958C2 (de) 1999-07-14 2003-08-07 Walter Schubert Vorrichtung zur Bindung von Molekülen, Molekülgruppen, Molekülteilen und/oder Zellen
AU784568B2 (en) 1999-09-03 2006-05-04 Ramot At Tel-Aviv University Ltd Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US6187309B1 (en) * 1999-09-14 2001-02-13 Milkaus Laboratory, Inc. Method for treatment of symptoms of central nervous system disorders
US6294171B2 (en) * 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US6436401B1 (en) * 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
US6713058B2 (en) * 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
JP5362164B2 (ja) * 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
EP1172378A1 (en) * 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
AU2001297872B2 (en) 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US6716226B2 (en) * 2001-06-25 2004-04-06 Inscope Development, Llc Surgical clip
US7700751B2 (en) * 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
EP1373321A2 (en) 2001-01-29 2004-01-02 Idec Pharmaceuticals Corporation Modified antibodies and methods of use
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
EP1944040B1 (en) * 2001-08-17 2012-08-01 Washington University Assay method for Alzheimer's disease
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20110200609A1 (en) * 2002-09-12 2011-08-18 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
DE60331101D1 (de) * 2002-11-22 2010-03-11 Chugai Pharmaceutical Co Ltd Antikörper gegen geschädigtes gewebe
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2004095031A1 (en) 2003-04-24 2004-11-04 Universität Zürich Method of monitoring immunotherapy
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
UA93181C2 (ru) 2004-02-23 2011-01-25 Эли Лилли Энд Компани СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ
JPWO2005105998A1 (ja) 2004-04-27 2008-07-31 財団法人化学及血清療法研究所 ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
WO2006050041A2 (en) 2004-10-28 2006-05-11 Ramot At Tel Aviv University Ltd. Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis
EP1838349A1 (en) * 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition
ES2340414T3 (es) 2005-03-05 2010-06-02 ABBOTT GMBH & CO. KG Metodo de seleccion, proceso para la purificacion de oligomeros de a-beta no-difusibles, anticuerpos selectivos contra dichos oligomeros de a-beta no-difusibles y un proceso para la fabricacion de dichos anticuerpos.
JP2006265189A (ja) 2005-03-24 2006-10-05 Kyoto Univ βアミロイドペプチド、及びそれを用いたアルツハイマー病治療薬又は予防薬のスクリーニング方法
ES2318918B1 (es) 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
MY148086A (en) * 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
EP1951892A4 (en) * 2005-11-22 2009-01-14 Univ Pennsylvania ANTIBODY TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISEASES
PL1976877T5 (pl) * 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
WO2007064917A2 (en) * 2005-11-30 2007-06-07 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
US8691224B2 (en) * 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
WO2007068412A2 (en) 2005-12-12 2007-06-21 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN103408661B (zh) * 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
JP5558834B2 (ja) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
US20080292625A1 (en) 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) * 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
US9370531B2 (en) * 2007-08-31 2016-06-21 New York University Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
EP2185592B1 (en) 2007-09-13 2013-01-23 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
AU2008307144B2 (en) * 2007-10-02 2012-12-20 Csl Limited Therapeutic antibody purification method and method of use
EP2210901A4 (en) 2007-10-19 2012-04-25 Immunas Pharma Inc FOR THE SPECIFIC BINDING TO AN OLIGOMICALLY ABLE ANTIBODY AND ITS USE
GB0720912D0 (en) * 2007-10-25 2007-12-05 Univ Cardiff Monoclonal Anitbody for APP
WO2009056490A1 (en) * 2007-10-29 2009-05-07 Innogenetics Nv NEW ANTIBODIES SPECIFIC OF THE β-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
HUE033825T2 (en) * 2007-11-16 2018-01-29 Univ Rockefeller Beta-amyloid protein protofibrillum-specific antibodies
JP5113853B2 (ja) * 2008-02-08 2013-01-09 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
JP2011527338A (ja) * 2008-07-09 2011-10-27 ユニバーシティー オブ チューリッヒ 神経新生を促進する方法
CA2742771A1 (en) * 2008-11-13 2010-05-20 Modgene, Llc Modification of amyloid-beta load in non-brain tissue
US9090679B2 (en) * 2009-04-17 2015-07-28 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
JP5599454B2 (ja) * 2009-08-06 2014-10-01 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
JP5769316B2 (ja) * 2009-08-06 2015-08-26 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用

Also Published As

Publication number Publication date
EP2426143A2 (en) 2012-03-07
US20100202968A1 (en) 2010-08-12
PL2099826T3 (pl) 2014-04-30
WO2008081008A1 (en) 2008-07-10
KR20160102079A (ko) 2016-08-26
CN101622275B (zh) 2013-11-06
KR20090114388A (ko) 2009-11-03
AU2008203703B2 (en) 2013-09-05
PL2436696T3 (pl) 2017-10-31
EP2099826B1 (en) 2013-10-16
ES2635317T3 (es) 2017-10-03
EP2436696B8 (en) 2017-12-13
EP3239174A1 (en) 2017-11-01
SG177954A1 (en) 2012-02-28
PT2099826E (pt) 2014-01-09
HUE033325T2 (en) 2017-11-28
PT2436696T (pt) 2017-08-21
JP5398545B2 (ja) 2014-01-29
EA017611B1 (ru) 2013-01-30
PT2426143T (pt) 2017-09-22
DK2436696T3 (en) 2017-09-04
EP2099826A1 (en) 2009-09-16
SI2436696T1 (sl) 2017-10-30
BRPI0806328B1 (pt) 2020-07-14
CN103408661B (zh) 2016-04-06
CN101622275A (zh) 2010-01-06
EA201201067A1 (ru) 2013-10-30
MX2009007136A (es) 2009-09-24
KR20160015402A (ko) 2016-02-12
CA2674140A1 (en) 2008-07-10
AU2008203703A1 (en) 2008-07-10
BRPI0806328A2 (pt) 2011-09-06
EP2436696A1 (en) 2012-04-04
KR101700073B1 (ko) 2017-01-26
HUE034512T2 (en) 2018-02-28
PL2426143T3 (pl) 2017-12-29
KR101735257B1 (ko) 2017-05-12
CY1119197T1 (el) 2018-02-14
LT2436696T (lt) 2017-08-25
KR20120017469A (ko) 2012-02-28
CA2764852A1 (en) 2008-07-10
CN103408661A (zh) 2013-11-27
DK2426143T3 (en) 2017-09-11
JP2010514454A (ja) 2010-05-06
EP2426143A3 (en) 2012-06-13
AU2008203703C1 (en) 2014-04-03
US8906367B2 (en) 2014-12-09
EA029481B1 (ru) 2018-04-30
CN102603893A (zh) 2012-07-25
CA2764852C (en) 2018-09-18
BRPI0806328B8 (pt) 2021-05-25
ES2641897T3 (es) 2017-11-14
EP2436696B1 (en) 2017-06-07
DK2099826T3 (da) 2014-01-20
EA200900954A1 (ru) 2010-02-26
EP2426143B1 (en) 2017-06-28
EP3239175A1 (en) 2017-11-01
CA2674140C (en) 2018-05-15
ES2439490T3 (es) 2014-01-23

Similar Documents

Publication Publication Date Title
LT2436696T (lt) Anti-beta-amiloido antikūnas ir jo panaudojimas
HRP20180596T1 (hr) PROTUTIJELA PROTIV Sp35 I NJIHOVA UPOTREBA
IL205355A0 (en) Anti- hepcidin antibodies and uses thereof
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
ZA200900351B (en) Prlr-specific antibody and uses thereof
IL195658A0 (en) Anti-nkg2a antibodies and uses thereof
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
IL216731A (en) And antibodies against p95 – her2 and their uses
IL201020A0 (en) C5 antigens and uses thereof
IL201156A0 (en) ANTI-IgE ANTIBODIES AND USES THEREOF
HK1203206A1 (en) Antibody and use thereof
HK1156326A1 (en) Anti-hepcidin-25 selective antibodies and uses thereof
EP2193144A4 (en) ANTIBODIES TO FLAGELLIN AND APPLICATIONS THEREOF
GB0812277D0 (en) Antibody and uses thereof
ZA200905136B (en) Anti-robo4 antibodies and uses therefor
GB0711398D0 (en) Substituted organpolysiloxanes and uses thereof